{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063774","form_type":"8-K/A","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.868892+00:00","generated_at":"2026-06-08T03:58:54.884035+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SAB Biotherapeutics raises $67.154M in Series A-1 Preferred; restructures warrant tranches","bullets":["Initially issued 7,500 Series A-1 Preferred shares for $7.5M on Oct 2, 2023.","Exercised Tranche A warrants: 59,654 additional shares for $59.654M by Nov 14.","Investors assumed 16,269 unexercised warrants; received new Tranche B and C warrants.","Outstanding now: 42,846 Tranche B warrants ($42.846M) and 107,115 Tranche C warrants ($107.115M).","Unexercised Tranche A warrants and remaining Tranche B/C warrants cancelled."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063774","json":"https://secwatch.observer/filing/0000950170-23-063774.json","markdown":"https://secwatch.observer/filing/0000950170-23-063774.md","text":"https://secwatch.observer/filing/0000950170-23-063774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023063774/0000950170-23-063774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023063774/sabs-20230929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:58:54.884035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}